外周动脉疾病口服抗血栓治疗选择:实践者指南
本综述旨在指导实践者处理下肢外周动脉疾病患者抗血栓治疗中的确定性与不确定性,并提供安全有效应用这些治疗以优化患者结局的框架。综述指出外周动脉疾病诊断不足且治疗不足,慢性抗血栓治疗在预防血栓事件中起关键作用,近期关于「双通路抑制」的重要文献帮助明确了有症状患者的最佳抗血栓实践,并对美欧加指南更新产生重大影响。
要点
- 双通路抑制(低剂量利伐沙班联合低剂量阿司匹林)应考虑用于所有有症状的外周动脉疾病患者。
- 药师在重新评估所有外周动脉疾病患者的抗血栓方案中发挥重要作用。
- 近期里程碑文献已导致国际指南发生实质性变化。
核心结论
- 双通路抑制即联合低剂量利伐沙班与低剂量阿司匹林治疗,应考虑用于所有有症状的外周动脉疾病患者。
- 药师在重新评估所有外周动脉疾病患者的抗血栓方案中发挥重要作用。
研究设计与样本
- 本综述旨在指导实践者处理下肢外周动脉疾病患者抗血栓治疗中的确定性与不确定性,并提供安全有效应用治疗的框架。
主要发现
- 外周动脉疾病是一种诊断不足且治疗不足的疾病。
- 慢性抗血栓治疗在预防下肢外周动脉疾病患者血栓事件中起关键作用。
- 关于抗血小板治疗、口服抗凝或两者联合何种最适合预防主要心血管和肢体事件,一直是长期临床问题。
- 真实世界实践中,长期使用的药物和剂量强度存在很大变异性。
- 近期关于「双通路抑制」的主要文献帮助明确了有症状外周动脉疾病患者的最佳抗血栓实践,并对美欧加近期更新指南产生重大影响。
临床怎么用
- 药师应重新评估所有外周动脉疾病患者的抗血栓方案。
- 对有症状的外周动脉疾病患者应考虑双通路抑制,即联合低剂量利伐沙班与低剂量阿司匹林治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this review is to guide practitioners through the certainty, and uncertainty, that surrounds optimal management of antithrombotic therapies in patients with lower-extremity peripheral arterial disease. It also provides practitioners with a framework from which to apply these therapies safely and effectively to optimize patient outcomes. SUMMARY: Peripheral arterial disease is an underdiagnosed and undertreated disease entity. Chronic antithrombotic therapies play a pivotal role in the prevention of thrombotic events in patients with lower-extremity peripheral arterial disease. Whether antiplatelet therapy, oral anticoagulation, or a combination of antiplatelet and anticoagulant therapies is best suited to prevent major cardiovascular and limb events in this patient population has been a long-standing clinical question. There is a great deal of variability in real-world practice as to which agents and dose intensities are used chronically for this purpose. Recent major publications exploring the use of "dual-pathway inhibition" have helped clarify best antithrombotic practices in patients with symptomatic peripheral arterial disease, and these have had a major impact on recently updated guidelines in the US, Europe, and Canada. CONCLUSION: Pharmacists play an important role in reevaluating antithrombotic regimens for all patients with peripheral arterial disease, recognizing that recent landmark publications have led to substantial changes to international guidelines. Dual-pathway inhibition with combined low-dose rivaroxaban and low-dose aspirin therapy should be considered in all patients with symptomatic peripheral arterial disease.
引用
- Vandiver JW. Selecting oral antithrombotic therapies in peripheral arterial disease: A guide for practitioners. Am J Health Syst Pharm. 2025. PMID: 40569251. doi:10.1093/ajhp/zxaf157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。